Form 4: Inovio Pharmaceuticals, Inc. (INO), Shea Jacqueline Elizabeth, transaction 02/26/2021

Summary

Jacqueline E. Shea, Chief Operating Officer of INOVIO PHARMACEUTICALS, INC. [ INO ], reports two awards dated 02/26/2021: a Common Stock Option for 104,833 shares at an exercise price of $ 11.1, expiring 02/26/2031, and 67,633 Restricted Stock Units. The option vests 26,208 shares on February 26, 2021 and on each of the next two anniversaries, with 26,209 on February 26, 2024. The units vest 22,544 shares on February 26, 2022 and February 26, 2023 and 22,545 on February 26, 2024, and each is a contingent right to one share of common stock. The form is signed /s/ Jacqueline E. Shea, 02/26/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Shea Jacqueline Elizabeth (Last) (First) (Middle) 660 W. GERMANTOWN PIKE (Street) PLYMOUTH MEETING PA 19462 (City) (State) (Zip) | Shea Jacqueline Elizabeth | (Last) | (First) | (Middle) | 660 W. GERMANTOWN PIKE | PLYMOUTH MEETING | PA | 19462 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Operating Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Operating Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 02/26/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Common Stock Option | $ 11.1 | 02/26/2021 | A | 104,833 | 02/26/2021 (1) | 02/26/2031 | Common Stock | 104,833 | $ 0 | 104,833 | D
Restricted Stock Unit | (2) | 02/26/2021 | A | 67,633 | (2) | (2) | Common Stock | 67,633 | $ 0 | 67,633 | D
Explanation of Responses:
1. The vesting schedule for the 104,833 options is as follows: 26,208 shares vested on February 26, 2021; 26,208 shares will vest on February 26, 2022; 26,208 shares will vest on February 26, 2023; 26,209 shares will vest on February 26, 2024.
2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Remarks:
/s/ Jacqueline E. Shea | 02/26/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2021-02-26_0001055726-21-000011.xml

Size

17,076 bytes

SHA-256

8752deaf68899108e069dad24e17407126c6b9a641150f397ee1d9f4c679ad1a

Our copy

SEC_INO_4_filed2021-02-26_0001055726-21-000011.xml

Original

www.sec.gov